Skip to main content
Top
Published in: Journal of Cancer Survivorship 2/2009

01-06-2009

Comorbidities, therapy, and newly diagnosed conditions for women with early stage breast cancer

Authors: Linda C. Harlan, Carrie N. Klabunde, Anita H. Ambs, Todd Gibson, Leslie Bernstein, Anne McTiernan, Kathleen Meeske, Kathy B. Baumgartner, Rachel Ballard-Barbash

Published in: Journal of Cancer Survivorship | Issue 2/2009

Login to get access

Abstract

Purpose

To describe comorbidities in breast cancer patients at diagnosis and examine factors associated with self-reported comorbidities 30 months post-diagnosis.

Methods

Nine hundred forty one of 1,171 women had a medical record abstract and a follow-up survey in the Health, Eating, Activity and Lifestyle Study.

Results

We compared our breast cancer cohort to a contemporaneous nationally-representative sample of age, race/ethnicity and education matched women without cancer (n = 865). Breast cancer patients did not have substantially more comorbidities than women without breast cancer. Women with a hospital record of congestive heart failure significantly less often received chemotherapy or radiation following breast conserving surgery. In multivariate analysis, women who received chemotherapy alone (OR = 3.2; 95% CI: 1.5–6.8), chemotherapy plus radiation (OR = 1.9; 95% CI: 1.02–3.7) or radiation plus tamoxifen (OR = 1.9; 95% CI: 1.1–3.2) were significantly more likely to report at least one new comorbid condition following breast cancer diagnosis than women who received no chemotherapy, tamoxifen or radiation. Overall, women who received adjuvant therapy were more likely to have new comorbidities.

Conclusions

Comorbidities were not substantially different in breast cancer patients than the non-cancer matched controls. Future research should focus on efforts to minimize comorbidities related to chemotherapy and other combination therapy.
Literature
1.
go back to reference American Cancer Society.Cancer Facts and Figures. Atlanta: American Cancer Society; 2007. American Cancer Society.Cancer Facts and Figures. Atlanta: American Cancer Society; 2007.
3.
go back to reference Yancik R, Wesley MN, Ries LAG, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients age 55 years and older. J Am Med Assoc. 2001;285:885–92. doi:10.1001/jama.285.7.885.CrossRef Yancik R, Wesley MN, Ries LAG, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients age 55 years and older. J Am Med Assoc. 2001;285:885–92. doi:10.​1001/​jama.​285.​7.​885.CrossRef
4.
7.
go back to reference Balasubramanian BA, Gandhi SK, Demissie K, et al. Use of adjuvant systemic therapy for early breast cancer among women 65 years of age and older. Cancer Control. 2007;14:63–68.PubMed Balasubramanian BA, Gandhi SK, Demissie K, et al. Use of adjuvant systemic therapy for early breast cancer among women 65 years of age and older. Cancer Control. 2007;14:63–68.PubMed
12.
go back to reference Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994;120:104–10.PubMed Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med. 1994;120:104–10.PubMed
13.
go back to reference Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. J Am Med Assoc. 2001;285:885–92. doi:10.1001/jama.285.7.885.CrossRef Yancik R, Wesley MN, Ries LA, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. J Am Med Assoc. 2001;285:885–92. doi:10.​1001/​jama.​285.​7.​885.CrossRef
19.
go back to reference Hurria A, Brogan K, Panageas KS, et al. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Breast Cancer Research and Treatmen. 2005;92:151–6. doi:10.1007/s10549-005-1410-8.CrossRef Hurria A, Brogan K, Panageas KS, et al. Patterns of toxicity in older patients with breast cancer receiving adjuvant chemotherapy. Breast Cancer Research and Treatmen. 2005;92:151–6. doi:10.​1007/​s10549-005-1410-8.CrossRef
20.
go back to reference Geiger AM, Gischberg GM, Chen W, Bernsein L. Stroke risk and tamoxifen therapy for breast cancer. J Natl Cancer Inst. 2004;96:1528–36.PubMedCrossRef Geiger AM, Gischberg GM, Chen W, Bernsein L. Stroke risk and tamoxifen therapy for breast cancer. J Natl Cancer Inst. 2004;96:1528–36.PubMedCrossRef
Metadata
Title
Comorbidities, therapy, and newly diagnosed conditions for women with early stage breast cancer
Authors
Linda C. Harlan
Carrie N. Klabunde
Anita H. Ambs
Todd Gibson
Leslie Bernstein
Anne McTiernan
Kathleen Meeske
Kathy B. Baumgartner
Rachel Ballard-Barbash
Publication date
01-06-2009
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 2/2009
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-009-0084-3

Other articles of this Issue 2/2009

Journal of Cancer Survivorship 2/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine